INS and Obesity: T2DM is predominantly associated with cardiovascular complications [22], while in patients with T2DM, the prevalence of MAFLD, severe fibrosis, and cirrhosis have been estimated to be 65%, 14%, and 6%, respectively, with obesity and insulin administration being predictors of fibrosis [23].